100-91: Silence Therapeutics to Blur Group

100-91: Silence Therapeutics to Blur Group


The rapid ascension of biotechnology outfit Silence Therapeutics’s (SLN) share price remains in large part a mystery – although one partly explained by the ever-growing presence of firebrand financier Richard Griffiths on the shareholder register. Beyond his 25 per cent interest, investor appetite for the largely untapped RNA Interface (RNAi) sequencing market is gathering pace. Subsequently, SLN has said it will look to “strengthen” its balance sheet following a peak in shareholder interest at the start of 2014.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now